Booth J C, Foster G R, Kumar U, Galassini R, Goldin R D, Brown J L, Thomas H C
Academic Department of Medicine, St Mary's Hospital Medical School, Imperial College of Science, Technology and Medicine, London.
Gut. 1995 Mar;36(3):427-32. doi: 10.1136/gut.36.3.427.
The effects of hepatitis C virus genotype and viraemia on disease outcome in patients with chronic hepatitis C virus infection were studied. Patients infected with genotype 1 tended to develop more severe disease, and to respond less well to interferon (IFN) treatment, but no pretreatment variable successfully predicted either the severity of the disease or the response to IFN. Failure to eliminate the virus during the first three months of therapy, however, predicted a failure to derive long term benefit from the current IFN regime. Hence pretreatment variables cannot be used to determine whether individual patients will respond to IFN, but observations during the first three months of therapy can be used to decide which patients will not respond to prolonged therapy. In these patients consideration should be given to changing the IFN dosing regime or using alternative treatments.
研究了丙型肝炎病毒基因型和病毒血症对慢性丙型肝炎病毒感染患者疾病转归的影响。感染1型基因型的患者往往会发展为更严重的疾病，并且对干扰素（IFN）治疗的反应较差，但没有任何治疗前变量能够成功预测疾病的严重程度或对IFN的反应。然而，在治疗的前三个月未能清除病毒，则预示着无法从当前的IFN治疗方案中获得长期益处。因此，治疗前变量不能用于确定个体患者是否会对IFN产生反应，但治疗前三个月的观察结果可用于决定哪些患者对延长治疗无反应。对于这些患者，应考虑改变IFN给药方案或使用替代治疗方法。
